News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Policy
Galenica Pharmaceuticals, Daiichi Sankyo, Inc. Drug Poses Risks, U.S. FDA Staff Says
January 31, 2008
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
Jan. 30 (Bloomberg) -- Daiichi Sankyo Co.'s drug Injectafer, which the company proposed selling for iron deficiency anemia, may pose ``serious safety concerns,'' U.S. regulators said.
Twitter
LinkedIn
Facebook
Email
Print
Regulatory
Europe
Food and Drug Administration (FDA)
Daiichi Sankyo
MORE ON THIS TOPIC
Regulatory
FDA Mulls National Priority Vouchers for Two Potential Merck Blockbusters: Report
December 18, 2025
·
2 min read
·
Tristan Manalac
Vaccines
CDC Formally Adopts Delayed Hepatitis B Vaccine Dose
December 17, 2025
·
4 min read
·
Tristan Manalac
Podcast
Lilly’s Triple Triumph, Prasad’s COVID Error, J&J’s Surprise Voucher, M&A Targets
December 17, 2025
·
2 min read
·
Heather McKenzie
Insights
Uptick in Dealmaking, Chinese Partnerships Drive Biotech’s Comeback
December 17, 2025
·
3 min read
·
Jennifer Smith-Parker